DK0735896T3 - Parathyroideahormonformulering - Google Patents
ParathyroideahormonformuleringInfo
- Publication number
- DK0735896T3 DK0735896T3 DK95903732T DK95903732T DK0735896T3 DK 0735896 T3 DK0735896 T3 DK 0735896T3 DK 95903732 T DK95903732 T DK 95903732T DK 95903732 T DK95903732 T DK 95903732T DK 0735896 T3 DK0735896 T3 DK 0735896T3
- Authority
- DK
- Denmark
- Prior art keywords
- parathyroid hormone
- hormone formulation
- excipient
- buffering agent
- formulation
- Prior art date
Links
- 239000000199 parathyroid hormone Substances 0.000 title abstract 3
- 108090000445 Parathyroid hormone Proteins 0.000 title abstract 2
- 102000003982 Parathyroid hormone Human genes 0.000 title abstract 2
- 229960001319 parathyroid hormone Drugs 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000006172 buffering agent Substances 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 abstract 1
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 102000058004 human PTH Human genes 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/172,206 US5496801A (en) | 1993-12-23 | 1993-12-23 | Parathyroid hormone formulation |
| PCT/CA1994/000693 WO1995017207A1 (en) | 1993-12-23 | 1994-12-16 | Parathyroid hormone formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0735896T3 true DK0735896T3 (da) | 2008-02-04 |
Family
ID=22626763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK95903732T DK0735896T3 (da) | 1993-12-23 | 1994-12-16 | Parathyroideahormonformulering |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5496801A (ja) |
| EP (2) | EP0735896B1 (ja) |
| JP (1) | JP3065662B2 (ja) |
| KR (1) | KR100398461B1 (ja) |
| CN (1) | CN1116897C (ja) |
| AT (1) | ATE374621T1 (ja) |
| AU (1) | AU681737B2 (ja) |
| BR (1) | BR9408398A (ja) |
| CA (1) | CA2179207C (ja) |
| CZ (1) | CZ184296A3 (ja) |
| DE (1) | DE69435033T2 (ja) |
| DK (1) | DK0735896T3 (ja) |
| ES (1) | ES2293637T3 (ja) |
| FI (1) | FI120291B (ja) |
| HK (1) | HK1010336A1 (ja) |
| HU (1) | HUT74381A (ja) |
| LV (1) | LV11731B (ja) |
| NO (1) | NO324905B1 (ja) |
| NZ (1) | NZ277463A (ja) |
| PL (1) | PL315158A1 (ja) |
| PT (1) | PT735896E (ja) |
| SK (1) | SK82896A3 (ja) |
| WO (1) | WO1995017207A1 (ja) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5563122A (en) * | 1991-12-09 | 1996-10-08 | Asahi Kasei Kogyo Kabushiki Kaisha | Stabilized parathyroid hormone composition |
| US6509316B2 (en) * | 1995-03-07 | 2003-01-21 | George Washington University | Pharmaceutical compositions, methods, and kits for treatment and diagnosis of lung cancer |
| SE9702401D0 (sv) * | 1997-06-19 | 1997-06-19 | Astra Ab | Pharmaceutical use |
| AU8356198A (en) * | 1997-07-22 | 1999-02-16 | Chugai Seiyaku Kabushiki Kaisha | Dental remedies containing pth |
| US6770623B1 (en) * | 1997-12-09 | 2004-08-03 | Eli Lilly And Company | Stabilized teriparatide solutions |
| ZA9811127B (en) * | 1997-12-09 | 2000-07-11 | Lilly Co Eli | Stabilized teriparatide solutions. |
| US6590081B1 (en) * | 1997-12-18 | 2003-07-08 | Eli Lilly And Company | Crystalline teriparatide |
| SE9801495D0 (sv) * | 1998-04-28 | 1998-04-28 | Astra Ab | Protein formulationa |
| JP4486256B2 (ja) * | 1998-10-22 | 2010-06-23 | ザ・ジェネラル・ホスピタル・コーポレイション | 副甲状腺ホルモン（ＰＴＨ）および副甲状腺ホルモン関連ペプチド（ＰＴＨｒＰ）の生物活性ペプチドおよびペプチド誘導体 |
| WO2000032771A1 (en) * | 1998-11-30 | 2000-06-08 | The General Hospital Corporation | Pth1r and pth3r receptors, methods and uses thereof |
| US7820393B2 (en) * | 1999-01-14 | 2010-10-26 | Scantibodies Laboratory, Inc. | Methods, kits and antibodies for detecting parathyroid hormone |
| US6689566B1 (en) | 1999-01-14 | 2004-02-10 | Scantibodies Laboratory, Inc. | Methods, kits, and antibodies for detecting parathyroid hormone |
| US20080108086A1 (en) * | 1999-06-02 | 2008-05-08 | Cantor Thomas L | Parathyroid hormone antagonists and uses thereof |
| US7893021B2 (en) * | 1999-06-02 | 2011-02-22 | Scantibodies Laboratory, Inc. | Parathyroid hormone antagonists and uses thereof |
| MXPA02000404A (es) * | 1999-07-12 | 2004-05-21 | Grandis Biotech Gmbh | Formulaciones de hormona de crecimiento. |
| WO2001023521A2 (en) * | 1999-09-29 | 2001-04-05 | The General Hospital Corporation | Polypeptide derivatives of parathyroid hormone (pth) |
| AU783952B2 (en) | 2000-02-04 | 2006-01-05 | Unigene Laboratories, Inc. | Nasal calcitonin formulations |
| CA2380423A1 (en) * | 2000-05-17 | 2001-11-22 | Bionebraska, Inc. | Peptide pharmaceutical formulations |
| US6387711B1 (en) * | 2000-08-11 | 2002-05-14 | Quest Diagnostics Investments Incorporated | Liquid intact parathyroid hormone (PTH) standards |
| US6905886B2 (en) * | 2000-08-11 | 2005-06-14 | Quest Diagnostics Investments Incorporated | Preservative solutions |
| EP1339312B1 (en) * | 2000-10-10 | 2006-01-04 | Microchips, Inc. | Microchip reservoir devices using wireless transmission of power and data |
| KR100491737B1 (ko) * | 2001-07-20 | 2005-05-27 | 주식회사 한국아이템개발 | 공기 정화 기능의 모기 퇴치기 |
| WO2003009804A2 (en) | 2001-07-23 | 2003-02-06 | The General Hospital Corporation | Conformationally constrained parathyroid hormone (pth) analogs |
| WO2004022033A1 (en) * | 2002-09-04 | 2004-03-18 | Microchips, Inc. | Method and device for the controlled delivery of parathyroid hormone |
| US20040067526A1 (en) * | 2002-10-03 | 2004-04-08 | Cantor Thomas L. | Methods for diagnosing and guiding treatment of bone turnover disease |
| WO2004093902A1 (en) * | 2003-03-19 | 2004-11-04 | The General Hospital Corporation | CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH α-HELIX STABILIZERS |
| EP1638523B8 (en) * | 2003-06-30 | 2013-12-25 | ALZA Corporation | Formulations for coated microprojections containing non-volatile counterions |
| KR100540659B1 (ko) * | 2003-07-02 | 2006-01-10 | 삼성전자주식회사 | 이미지 확대 인쇄 방법과 장치 및 컴퓨터 프로그램을저장하는 컴퓨터로 읽을 수 있는 기록 매체 |
| WO2005014034A1 (en) * | 2003-07-14 | 2005-02-17 | Nps Allelix Corp. | Stabilized formulation of parathyroid hormone |
| WO2005009358A2 (en) | 2003-07-17 | 2005-02-03 | The General Hospital Corporation | Conformationally constrained parathyroid hormone (pth) analogs |
| US7459276B2 (en) * | 2003-09-29 | 2008-12-02 | Scantibodies Laboratory, Inc. | Methods and controls for monitoring assay quality and accuracy in parathyroid hormone measurement |
| US20050119183A1 (en) * | 2003-11-12 | 2005-06-02 | Nps Allelix Corp. | Method for treating bone loss using parathyroid hormone |
| AU2004292954A1 (en) * | 2003-11-13 | 2005-06-09 | Alza Corporation | Composition and apparatus for transdermal delivery |
| CN100406059C (zh) * | 2004-04-30 | 2008-07-30 | 陈新梅 | 甲状旁腺激素的新用途 |
| AU2005244734A1 (en) * | 2004-05-13 | 2005-12-01 | Alza Corporation | Apparatus and method for transdermal delivery of parathyroid hormone agents |
| US7541140B2 (en) * | 2004-06-03 | 2009-06-02 | Scantibodies Laboratory, Inc. | Assessing risk for kidney stones using parathyroid hormone agonist and antagonist |
| US20080076975A1 (en) * | 2005-01-25 | 2008-03-27 | Microchips, Inc. | Method and implantable device with reservoir array for pre-clinical in vivo testing |
| US7488316B2 (en) * | 2005-01-25 | 2009-02-10 | Microchips, Inc. | Control of drug release by transient modification of local microenvironments |
| KR100700869B1 (ko) | 2005-06-03 | 2007-03-29 | 재단법인 목암생명공학연구소 | Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물 |
| WO2007059470A2 (en) * | 2005-11-10 | 2007-05-24 | Board Of Control Of Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| WO2008019062A2 (en) * | 2006-08-04 | 2008-02-14 | The General Hospital Corporation | Polypeptide derivatives of parathyroid hormone (pth) |
| EP1961765A1 (en) * | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Truncated PTH peptides with a cyclic conformation |
| US8568737B2 (en) | 2007-08-01 | 2013-10-29 | The General Hospital Corporation | Screening methods using G-protein coupled receptors and related compositions |
| EP2173768B1 (en) * | 2007-08-09 | 2014-03-05 | USV Limited | Novel orthogonal process for purification of recombinant human parathyroid hormone (rhpth) (1-34) |
| JP2009091363A (ja) * | 2008-11-21 | 2009-04-30 | Asahi Kasei Pharma Kk | Ｐｔｈの安定化水溶液注射剤 |
| JP2013512688A (ja) | 2009-12-07 | 2013-04-18 | ミシガン テクノロジカル ユニバーシティ | クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法 |
| JP5941040B2 (ja) | 2010-05-13 | 2016-06-29 | ザ ジェネラル ホスピタル コーポレイション | 副甲状腺ホルモン類似体およびその使用 |
| CN103442695B (zh) * | 2011-03-10 | 2016-05-04 | Xeris药物公司 | 肠胃外注射用肽药物的稳定制剂 |
| KR101792473B1 (ko) * | 2011-06-07 | 2017-10-31 | 아사히 가세이 파마 가부시키가이샤 | 고순도 ｐｔｈ 함유 동결 건조 제제 및 그의 제조 방법 |
| JP2016512839A (ja) | 2013-03-15 | 2016-05-09 | シヴィダ・ユーエス・インコーポレイテッドＰｓｉｖｉｄａ Ｕｓ， Ｉｎｃ． | 治療物質の送達のための生体内分解性ケイ素系組成物 |
| CN103301058A (zh) * | 2013-06-17 | 2013-09-18 | 深圳翰宇药业股份有限公司 | 一种特立帕肽注射用组合物及其制备方法和制剂 |
| JP7399382B2 (ja) * | 2018-07-30 | 2023-12-18 | 武田薬品工業株式会社 | 組換えヒト副甲状腺ホルモンの安定性を向上させるための製剤 |
| CN110917150A (zh) * | 2019-12-31 | 2020-03-27 | 北京博康健基因科技有限公司 | 一种pth冻干制剂及其制备方法 |
| EP4110370A4 (en) * | 2020-03-30 | 2023-06-07 | Sichuan Luzhou Buchang Bio-Pharmaceutical Co., Ltd. | FORMULATIONS OF HUMAN PARATHYROID HORMONE (PTH) AND METHODS OF MANUFACTURE THEREOF |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3768177A (en) * | 1972-08-02 | 1973-10-30 | R Thomas | Educational device |
| US4105602A (en) * | 1975-02-10 | 1978-08-08 | Armour Pharmaceutical Company | Synthesis of peptides with parathyroid hormone activity |
| US4016314A (en) * | 1975-06-26 | 1977-04-05 | Hallco Inc. | Embroidered fruit bowl wall hanging and kit for making same |
| US4199060A (en) * | 1978-07-20 | 1980-04-22 | Howard Hardware Products, Inc. | Lock installation kit |
| US4424278A (en) * | 1981-11-16 | 1984-01-03 | Research Corporation | Cancer detection procedure using an acyl carrier protein |
| JPS61267528A (ja) * | 1984-11-26 | 1986-11-27 | Yamanouchi Pharmaceut Co Ltd | 吸収促進剤を含有するカルシトニン経鼻剤 |
| US4812311A (en) * | 1984-12-21 | 1989-03-14 | The Procter & Gamble Company | Kit for use in the treatment of osteoporosis |
| IL78342A (en) * | 1985-04-04 | 1991-06-10 | Gen Hospital Corp | Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof |
| JPS6360940A (ja) * | 1986-09-01 | 1988-03-17 | Toyo Jozo Co Ltd | 白内障の予防または治療剤 |
| US4833125A (en) * | 1986-12-05 | 1989-05-23 | The General Hospital Corporation | Method of increasing bone mass |
| US5059587A (en) * | 1987-08-03 | 1991-10-22 | Toyo Jozo Company, Ltd. | Physiologically active peptide composition for nasal administration |
| US5011678A (en) * | 1989-02-01 | 1991-04-30 | California Biotechnology Inc. | Composition and method for administration of pharmaceutically active substances |
| DE3935738A1 (de) * | 1989-10-27 | 1991-05-08 | Forssmann Wolf Georg | Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff |
| GB9020544D0 (en) * | 1990-09-20 | 1990-10-31 | Sandoz Ltd | Improvements in or relating to organic compounds |
| JP3090353B2 (ja) * | 1991-09-17 | 2000-09-18 | 旭化成工業株式会社 | パラチロイドホルモン類含有経鼻投与用乳剤 |
| US5563122A (en) * | 1991-12-09 | 1996-10-08 | Asahi Kasei Kogyo Kabushiki Kaisha | Stabilized parathyroid hormone composition |
| CA2124792C (en) * | 1991-12-17 | 2000-07-04 | Ann D. Geddes | Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone |
| IT1255723B (it) * | 1992-10-09 | 1995-11-13 | Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione |
-
1993
- 1993-12-23 US US08/172,206 patent/US5496801A/en not_active Expired - Lifetime
-
1994
- 1994-12-16 JP JP7517064A patent/JP3065662B2/ja not_active Expired - Lifetime
- 1994-12-16 CZ CZ961842A patent/CZ184296A3/cs unknown
- 1994-12-16 BR BR9408398A patent/BR9408398A/pt not_active Application Discontinuation
- 1994-12-16 DE DE69435033T patent/DE69435033T2/de not_active Expired - Lifetime
- 1994-12-16 SK SK828-96A patent/SK82896A3/sk unknown
- 1994-12-16 EP EP95903732A patent/EP0735896B1/en not_active Expired - Lifetime
- 1994-12-16 NZ NZ277463A patent/NZ277463A/en not_active IP Right Cessation
- 1994-12-16 AU AU12698/95A patent/AU681737B2/en not_active Expired
- 1994-12-16 AT AT95903732T patent/ATE374621T1/de active
- 1994-12-16 ES ES95903732T patent/ES2293637T3/es not_active Expired - Lifetime
- 1994-12-16 PL PL94315158A patent/PL315158A1/xx unknown
- 1994-12-16 CN CN94194608A patent/CN1116897C/zh not_active Expired - Lifetime
- 1994-12-16 DK DK95903732T patent/DK0735896T3/da active
- 1994-12-16 PT PT95903732T patent/PT735896E/pt unknown
- 1994-12-16 HU HU9601721A patent/HUT74381A/hu unknown
- 1994-12-16 EP EP07019169A patent/EP1880732A1/en not_active Withdrawn
- 1994-12-16 KR KR1019960703288A patent/KR100398461B1/ko not_active IP Right Cessation
- 1994-12-16 WO PCT/CA1994/000693 patent/WO1995017207A1/en active IP Right Grant
- 1994-12-16 CA CA002179207A patent/CA2179207C/en not_active Expired - Lifetime
-
1996
- 1996-06-20 FI FI962593A patent/FI120291B/fi not_active IP Right Cessation
- 1996-06-20 NO NO19962634A patent/NO324905B1/no not_active IP Right Cessation
- 1996-07-19 LV LVP-96-283A patent/LV11731B/en unknown
-
1998
- 1998-10-08 HK HK98111127A patent/HK1010336A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NO324905B1 (no) | 2007-12-27 |
| DE69435033T2 (de) | 2008-05-29 |
| CZ184296A3 (en) | 1997-01-15 |
| CA2179207C (en) | 2000-11-14 |
| EP1880732A1 (en) | 2008-01-23 |
| PT735896E (pt) | 2007-12-07 |
| CN1142772A (zh) | 1997-02-12 |
| NO962634D0 (no) | 1996-06-20 |
| HUT74381A (en) | 1996-12-30 |
| ATE374621T1 (de) | 2007-10-15 |
| AU1269895A (en) | 1995-07-10 |
| EP0735896B1 (en) | 2007-10-03 |
| NZ277463A (en) | 1997-03-24 |
| LV11731A (lv) | 1997-04-20 |
| FI962593A0 (fi) | 1996-06-20 |
| FI962593A (fi) | 1996-08-19 |
| AU681737B2 (en) | 1997-09-04 |
| ES2293637T3 (es) | 2008-03-16 |
| WO1995017207A1 (en) | 1995-06-29 |
| CA2179207A1 (en) | 1995-06-29 |
| FI120291B (fi) | 2009-09-15 |
| HU9601721D0 (en) | 1996-08-28 |
| SK82896A3 (en) | 1997-01-08 |
| KR100398461B1 (ko) | 2004-03-20 |
| EP0735896A1 (en) | 1996-10-09 |
| BR9408398A (pt) | 1997-08-12 |
| US5496801A (en) | 1996-03-05 |
| DE69435033D1 (de) | 2007-11-15 |
| JPH09506869A (ja) | 1997-07-08 |
| PL315158A1 (en) | 1996-10-14 |
| HK1010336A1 (en) | 1999-06-17 |
| NO962634L (no) | 1996-06-20 |
| JP3065662B2 (ja) | 2000-07-17 |
| CN1116897C (zh) | 2003-08-06 |
| LV11731B (en) | 1997-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0735896T3 (da) | Parathyroideahormonformulering | |
| EP0619119A4 (en) | COMPOSITION BASED ON STABILIZED PARATHYROIDIAN HORMONE. | |
| ES2055845T3 (es) | Composicion farmaceutica para el tratamiento de la osteoporosis. | |
| UA72884C2 (uk) | Стабілізовані розчини паратирину | |
| BR9402902A (pt) | Hormônio paratiróideo e raloxifeno, compostos e formulação farmacêutica. | |
| IE882671L (en) | Stabilised human protein formulation | |
| CA2027592A1 (en) | Solid pharmaceutical preparations of active form of vitamin d_ of improved stability | |
| AU5561686A (en) | Method of increasing bone mass | |
| NO891007D0 (no) | Farmasoeytiske polypeptidholdige preparater. | |
| HUT62802A (en) | Process for producing locally applicable pharmaceutical compositions comprising collagenase in large dose | |
| NZ230280A (en) | Pharmaceutical formulation containing an insulin derivative modified with a base, with an isoelectric point between 5.8 - 8.5, and with a zinc ion content of from 2mug - 200mug of zinc/iu | |
| SE8504945L (sv) | Farmaceutiska kompositioner innehallande antracyklinglykosider | |
| ATE148630T1 (de) | Stabilisierte derivate von vitamin d2 und d3 enthaltende pharmazeutische zusammensetzungen | |
| DK0582239T3 (da) | Farmaceutisk og/eller kosmetisk formulering | |
| IL140140A0 (en) | Thyroid hormone analogues and methods for their preparation | |
| SE8803935L (sv) | Laekemedelskomposition | |
| GB2251188B (en) | Drug delivery system comprising a lysophosphoglycerolipid | |
| HRP20000781B1 (en) | Effervescent preparations | |
| IL87778A0 (en) | Pharmaceutical compositions containing stabilized therapeutically active proteins and their preparation | |
| IL92061A0 (en) | Pharmaceutical compositions containing biologically active peptides and certain anions | |
| IL103862A0 (en) | Stabilized pharmaceutical composition of non-glycosylated recombinant human il2 in reduced form and its preparation process | |
| DE69430996T2 (de) | Verfahren zur trockenmischungkompression von arzneimitteln | |
| EP0265338A3 (en) | Stable therapeutical compositions based on hydrophobic vegetable oil, and process for preparing them | |
| IT1247695B (it) | Composizioni farmaceutiche a base di calcitonina somministrabili per via nasale in terapia umana |